Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Selective R-cadherin antagonist and methods

a selective, cadherin technology, applied in the direction of angiogenin, extracellular fluid disorder, metabolism disorder, etc., can solve the problems of loss of cadherin function, molecule sensitivity to protease degradation in solution, and relatively little knowledge about the mechanism of specific homodimerization of cadherin molecules

Inactive Publication Date: 2008-09-02
THE SCRIPPS RES INST
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new peptide that can act as a selective antagonist of mammalian R-cadherin, a protein involved in cell-cell adhesion. The peptide has three contiguous amino acid residues that form a specific sequence, and can be used to inhibit R-cadherin-mediated cellular adhesion. The peptide can be administered to patients with abnormal retinal vascular angiogenesis or to target lineage negative hematopoietic stem cells to inhibit vasculature development. The technical effect of this patent is the development of a new tool to inhibit R-cadherin-mediated cellular adhesion, which could be useful in treating diseases associated with abnormal vascular development.

Problems solved by technology

Cadherin function is lost and molecules become more susceptible to protease degradation in solutions with insufficient concentrations of calcium ions (i.e., below about 2 mM).
However, relatively little is known about the mechanisms of specific homodimerization between cadherin molecules.
Disruption of R-cadherin adhesion during formation of the superficial vascular plexus results in the loss of complex vascular interconnections observed during normal vascular patterning.
Any disease or condition that alters the retinal layers even slightly, can lead to neuronal degeneration and significant visual loss.
However, as there is no evidence to suggest that these stem cells can undergo differentiation into retinal neurons or glial cells, the mechanism of neuronal protection remains unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Selective R-cadherin antagonist and methods
  • Selective R-cadherin antagonist and methods
  • Selective R-cadherin antagonist and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

Peptide Synthesis

[0060]The peptides of the present invention and various control peptides were synthesized by The Scripps Research Institute Protein and Nucleic Acids core facility using the solid phase synthesis method, and were purified to the highest grade possible (>95% pure) as analyzed by HPLC analysis. The sequences of the peptides were analyzed by mass spectrometry to ensure synthesis of the correct peptides. All peptides were amide blocked at the amino terminus and acetylated at the carboxy terminus. The cyclic peptides were prepared with cysteine residues at the amino and carboxy terminal ends to create a disulfide tether and form a ring containing five amino acid residues. FIG. 5 (B) illustrates the peptides prepared: cylic CIDSC (SEQ ID NO: 9), cylic CINPC (SEQ ID NO: 9), IDSMSGR (SEQ ID NO: 2), IDSASGR (SEQ ID NO: 10), INPASGO (SEQ ID NO: 11), cylic CSDIC (SEQ ID NO: 12), and cylic CRADC (SEQ ID NO: 13).

example 2

L-Cell Transfections

[0061]Mouse R-cadherin and N-cadherin plasmids were generous gifts from Dr. Masatoshi Takeichi (Kyoto University, Japan). The plasmids were sub-cloned into pDsRed2 N1 vectors (Clontech) to encode for fusion proteins with Red Fluorescent Protein (RFP) attached to the C-terminal end of the cadherin molecules. L-cells (mouse fibroblast L929 cells, ATCC #CRL-2148) were stably transfected with either R or N-cadherin pDsRed2 N1 using the Calcium Phosphate Transfection System (Life Technologies) according to the manufacturer's protocol. After screening by growth in media supplemented with Geneticin (700 μg / mL G418 Geneticin, Gibco BRL), positive clones were selected. Cells were examined for expression of RFP, and were tested for cadherin expression by immunoblotting and immunofluorescence staining. FIG. 6 illustrates the aggregation of L-cells expressing R and N-cadherins. FIG. 6(A) shows photomicrographs of R-cadherin (left) and N-cadherin (middle) expressing L-cells a...

example 3

Cell Culture and Immunofuorescence

[0062]Transfected or wild type L-cells were grown in Modified Eagles Medium (MEM) supplemented with Earl's Basic Salt Solution, 2 mM Glutamax, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, and 10% fetal bovine serum. Transfected cell lines were grown in media supplemented with about 700 μg / mL G418 (all media reagents were from Gibco BRL). For immunofluorescence, the cells were grown to about 75% confluency on glass cover slips. The cells were fixed in 4% paraformaldehyde for about one-half hour followed by blocking with 5% normal goat serum and 5% fetal bovine serum in 1× phosphate buffered saline (PBS). Goat polyclonal antibodies against R-cadherin or N-cadherin (Santa Cruz) were used at 1:200 dilution, and fluorescence was conferred by incubation with Alexa488 labeled anti-goat IgG secondaries (Molecular Probes). Images were created using a Radiance 200 fluorescence confocal microscope (BioRad). For immunoblot analysis, cells were lysed ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
cellular adhesionaaaaaaaaaa
adhesionaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

An isolated peptide useful as a selective antagonist of mammalian R-cadherin comprises 3 to 30 amino acid residues, three contiguous residues of the peptide having the amino acid sequence Ile-Xaa-Ser; wherein Xaa is an amino acid residue selected from the group consisting of Asp, Asn, Glu, and Gln. Preferably Xaa is Asp or Asn. In one preferred embodiment the peptide is a cyclic peptide having 3 to 10 amino acid residues arranged in a ring. The selective R-cadherin antagonist peptides of the invention are useful for inhibiting the targeting of stem cells, such as endothelial precursor cells, to developing vasculature, for inhibiting R-cadherin mediated cellular adhesion, and for inhibiting retinal angiogenesis.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application for Patent Ser. No. 60 / 467,188, filed on May 1, 2003, which is incorporated herein by reference.STATEMENT OF GOVERNMENT INTEREST[0002]This invention was made with United States government support under Grants No. EY11254 and EY12598 from the National Institutes of Health. The United States government has certain rights in this invention.FIELD OF THE INVENTION[0003]This invention relates generally to antagonists of mammalian cellular adhesion molecules. More specifically, the invention relates to selective peptide antagonists of mammalian R-cadherin (cadherin-4) and methods of inhibiting cellular adhesion and retinal angiogenesis therewith.BACKGROUND OF THE INVENTION[0004]The cadherin family of molecules consists of transmembrane glycoproteins that function in calcium dependent, selective cell-cell interactions. These molecules play important roles during embryonic develop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K38/00A61K38/06A61K38/08A61K38/10A61K38/12C07KC07K14/705
CPCC07K14/705A61K38/00A61P27/00A61P27/02A61P43/00A61P9/00A61P9/10C07K14/00
Inventor FRIEDLANDER, MARTINDORRELL, MICHAEL I.
Owner THE SCRIPPS RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com